The endocannabinoid system in Pakinson's disease

Massimiliano Di Filippo, Barbara Picconi, Alessandro Tozzi, Veronica Ghiglieri, Aroldo Rossi, Paolo Calabresi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder of largely unknown etiology caused by a pathological cascade resulting in the degeneration of midbrain dopaminergic neurons of the substantia nigra pars compacta (SNpc) projecting to the nucleus striatum, the main input station of the basal ganglia neuronal circuit. The components of the endocannabinoid (ECB) system are highly expressed at different levels in the basal ganglia neural circuit where they bidirectionally interact with dopaminergic, glutamatergic and GABAergic signaling systems. In particular, at synapses linking cortical and striatal neurons, endocannabinoids (ECBs) are known to critically modulate synaptic transmission and to mediate the induction of a particular form of synaptic plasticity, the long-term depression. The evidence that ECBs play a central role in regulating basal ganglia physiology and motor function and the profound modifications occurring in ECB signaling after dopamine depletion in both experimental models of PD and patients suffering from the disease, provide support for the development of pharmacological compounds targeting the ECB system as symptomatic and neuroprotective therapeutic strategies for PD.

Original languageEnglish
Pages (from-to)2337-2346
Number of pages10
JournalCurrent Pharmaceutical Design
Volume14
Issue number23
DOIs
Publication statusPublished - Aug 2008

Fingerprint

Endocannabinoids
Basal Ganglia
Parkinson Disease
Corpus Striatum
Neuronal Plasticity
Dopaminergic Neurons
Parkinsonian Disorders
Mesencephalon
Synaptic Transmission
Neurodegenerative Diseases
Synapses
Dopamine
Theoretical Models
Pharmacology
Neurons

Keywords

  • Endocannabinoids
  • Neuroinflammation
  • Parkinson's disease
  • Synaptic plasticity

ASJC Scopus subject areas

  • Drug Discovery
  • Pharmacology

Cite this

The endocannabinoid system in Pakinson's disease. / Di Filippo, Massimiliano; Picconi, Barbara; Tozzi, Alessandro; Ghiglieri, Veronica; Rossi, Aroldo; Calabresi, Paolo.

In: Current Pharmaceutical Design, Vol. 14, No. 23, 08.2008, p. 2337-2346.

Research output: Contribution to journalArticle

Di Filippo, Massimiliano ; Picconi, Barbara ; Tozzi, Alessandro ; Ghiglieri, Veronica ; Rossi, Aroldo ; Calabresi, Paolo. / The endocannabinoid system in Pakinson's disease. In: Current Pharmaceutical Design. 2008 ; Vol. 14, No. 23. pp. 2337-2346.
@article{83d7ecc7a461419087e1472d13b1ae81,
title = "The endocannabinoid system in Pakinson's disease",
abstract = "Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder of largely unknown etiology caused by a pathological cascade resulting in the degeneration of midbrain dopaminergic neurons of the substantia nigra pars compacta (SNpc) projecting to the nucleus striatum, the main input station of the basal ganglia neuronal circuit. The components of the endocannabinoid (ECB) system are highly expressed at different levels in the basal ganglia neural circuit where they bidirectionally interact with dopaminergic, glutamatergic and GABAergic signaling systems. In particular, at synapses linking cortical and striatal neurons, endocannabinoids (ECBs) are known to critically modulate synaptic transmission and to mediate the induction of a particular form of synaptic plasticity, the long-term depression. The evidence that ECBs play a central role in regulating basal ganglia physiology and motor function and the profound modifications occurring in ECB signaling after dopamine depletion in both experimental models of PD and patients suffering from the disease, provide support for the development of pharmacological compounds targeting the ECB system as symptomatic and neuroprotective therapeutic strategies for PD.",
keywords = "Endocannabinoids, Neuroinflammation, Parkinson's disease, Synaptic plasticity",
author = "{Di Filippo}, Massimiliano and Barbara Picconi and Alessandro Tozzi and Veronica Ghiglieri and Aroldo Rossi and Paolo Calabresi",
year = "2008",
month = "8",
doi = "10.2174/138161208785740072",
language = "English",
volume = "14",
pages = "2337--2346",
journal = "Current Pharmaceutical Design",
issn = "1381-6128",
publisher = "Bentham Science Publishers B.V.",
number = "23",

}

TY - JOUR

T1 - The endocannabinoid system in Pakinson's disease

AU - Di Filippo, Massimiliano

AU - Picconi, Barbara

AU - Tozzi, Alessandro

AU - Ghiglieri, Veronica

AU - Rossi, Aroldo

AU - Calabresi, Paolo

PY - 2008/8

Y1 - 2008/8

N2 - Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder of largely unknown etiology caused by a pathological cascade resulting in the degeneration of midbrain dopaminergic neurons of the substantia nigra pars compacta (SNpc) projecting to the nucleus striatum, the main input station of the basal ganglia neuronal circuit. The components of the endocannabinoid (ECB) system are highly expressed at different levels in the basal ganglia neural circuit where they bidirectionally interact with dopaminergic, glutamatergic and GABAergic signaling systems. In particular, at synapses linking cortical and striatal neurons, endocannabinoids (ECBs) are known to critically modulate synaptic transmission and to mediate the induction of a particular form of synaptic plasticity, the long-term depression. The evidence that ECBs play a central role in regulating basal ganglia physiology and motor function and the profound modifications occurring in ECB signaling after dopamine depletion in both experimental models of PD and patients suffering from the disease, provide support for the development of pharmacological compounds targeting the ECB system as symptomatic and neuroprotective therapeutic strategies for PD.

AB - Parkinson's disease (PD) is a chronic and progressive neurodegenerative disorder of largely unknown etiology caused by a pathological cascade resulting in the degeneration of midbrain dopaminergic neurons of the substantia nigra pars compacta (SNpc) projecting to the nucleus striatum, the main input station of the basal ganglia neuronal circuit. The components of the endocannabinoid (ECB) system are highly expressed at different levels in the basal ganglia neural circuit where they bidirectionally interact with dopaminergic, glutamatergic and GABAergic signaling systems. In particular, at synapses linking cortical and striatal neurons, endocannabinoids (ECBs) are known to critically modulate synaptic transmission and to mediate the induction of a particular form of synaptic plasticity, the long-term depression. The evidence that ECBs play a central role in regulating basal ganglia physiology and motor function and the profound modifications occurring in ECB signaling after dopamine depletion in both experimental models of PD and patients suffering from the disease, provide support for the development of pharmacological compounds targeting the ECB system as symptomatic and neuroprotective therapeutic strategies for PD.

KW - Endocannabinoids

KW - Neuroinflammation

KW - Parkinson's disease

KW - Synaptic plasticity

UR - http://www.scopus.com/inward/record.url?scp=52949114944&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=52949114944&partnerID=8YFLogxK

U2 - 10.2174/138161208785740072

DO - 10.2174/138161208785740072

M3 - Article

VL - 14

SP - 2337

EP - 2346

JO - Current Pharmaceutical Design

JF - Current Pharmaceutical Design

SN - 1381-6128

IS - 23

ER -